News
That controversial Super Bowl ad appears to have paid off for Hims & Hers as the company's first-quarter revenue doubled year ...
Hims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, ...
Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...
Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Nader ...
Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...
Hims & Hers Health (NYSE: HIMS) stock surged 23% on Tuesday, April 29, after Novo Nordisk announced plans to offer popular ...
Novo Nordisk said it would sell its popular weight-loss drug Wegovy on several telehealth platforms, including Hims.
Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on ...
Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...
Explore Hims & Hers' impressive Q1 2025 growth with 111% revenue increase, strategic partnerships, and innovative healthcare solutions.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback